{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T21:41:20Z","timestamp":1760910080025,"version":"build-2065373602"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003243","name":"Ministerstvo Zdravotnictv\u00ed Cesk\u00e9 Republiky","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.cyto.2020.155350","type":"journal-article","created":{"date-parts":[[2020,10,27]],"date-time":"2020-10-27T23:51:36Z","timestamp":1603842696000},"page":"155350","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Interleukin-35 in idiopathic inflammatory myopathies"],"prefix":"10.1016","volume":"137","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4243-235X","authenticated-orcid":false,"given":"He\u0159man","family":"Mann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga","family":"Kry\u0161t\u016ffkov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josef","family":"Z\u00e1me\u010dn\u00edk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jarom\u00edr","family":"H\u00e1\u010dek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hana","family":"Hulejov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00e1ria","family":"Filkov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji\u0159\u00ed","family":"Vencovsk\u00fd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ladislav","family":"\u0160enolt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cyto.2020.155350_b0005","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1002\/art.40320","article-title":"2017 European league against rheumatism\/American college of rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"69","author":"Lundberg","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.cyto.2020.155350_b0010","first-page":"75","article-title":"Triggers of inflammatory myopathy: insights into pathogenesis","volume":"25","author":"Adler","year":"2018","journal-title":"Discov. Med."},{"issue":"5","key":"10.1016\/j.cyto.2020.155350_b0015","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/nrrheum.2018.48","article-title":"Risk factors and disease mechanisms in myositis","volume":"14","author":"Miller","year":"2018","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.cyto.2020.155350_b0020","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1097\/BOR.0b013e3283317b31","article-title":"Role of cytokines and chemokines in idiopathic inflammatory myopathies","volume":"21","author":"De Paepe","year":"2009","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.cyto.2020.155350_b0025","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s12026-018-8998-3","article-title":"IL-35: a new immunomodulator in autoimmune rheumatic diseases","volume":"66","author":"Sakkas","year":"2018","journal-title":"Immunol. Res."},{"key":"10.1016\/j.cyto.2020.155350_b0030","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/nature06306","article-title":"The inhibitory cytokine IL-35 contributes to regulatory T-cell function","volume":"450","author":"Collison","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.cyto.2020.155350_b0035","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/nm.3554","article-title":"Interleukin-35 induces regulatory B cells that suppress autoimmune disease","volume":"20","author":"Wang","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.cyto.2020.155350_b0040","article-title":"IL-35 is a novel responsive anti-inflammatory cytokine\u2014a new system of categorizing anti-inflammatory cytokines","volume":"7","author":"Li","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.cyto.2020.155350_b0045","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0132674","article-title":"Interleukin 35 synovial fluid levels are associated with disease activity of rheumatoid arthritis","volume":"10","author":"\u0160enolt","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.cyto.2020.155350_b0050","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.cyto.2015.01.019","article-title":"Pro-inflammatory effects of interleukin-35 in rheumatoid arthritis","volume":"73","author":"Filkov\u00e1","year":"2015","journal-title":"Cytokine"},{"key":"10.1016\/j.cyto.2020.155350_b0055","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1159\/000471798","article-title":"New interleukins in psoriasis and psoriatic arthritis patients: the possible roles of interleukin-33 to interleukin-38 in disease activities and bone erosions","volume":"233","author":"Li","year":"2017","journal-title":"Dermatology"},{"key":"10.1016\/j.cyto.2020.155350_b0060","doi-asserted-by":"crossref","unstructured":"Tomcik M, Zerr P, Palumbo-Zerr et al. Interleukin-35 is upregulated in systemic sclerosis and its serum levels are associated with early disease. Rheumatology (Oxford) 2015; 54: 2273\u20132282.","DOI":"10.1093\/rheumatology\/kev260"},{"key":"10.1016\/j.cyto.2020.155350_b0065","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1007\/s10067-015-3006-y","article-title":"Increased IL-35 serum levels in systemic sclerosis and association with pulmonary interstitial involvement","volume":"34","author":"Dantas","year":"2015","journal-title":"Clin. Rheumatol."},{"issue":"2","key":"10.1016\/j.cyto.2020.155350_b0070","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/MAJ.0000000000000215","article-title":"Decreased interleukin 35 and CD4+EBI3+ T cells in patients with active systemic lupus erythematosus","volume":"348","author":"Ouyang","year":"2014","journal-title":"Am. J. Med. Sci."},{"key":"10.1016\/j.cyto.2020.155350_b0075","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1620\/tjem.244.263","article-title":"Interleukin-35 as a new biomarker of renal involvement in lupus nephritis patients","volume":"244","author":"He","year":"2018","journal-title":"Tohoku J. Exp. Med."},{"key":"10.1016\/j.cyto.2020.155350_b0080","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1007\/s10067-016-3347-1","article-title":"The clinical utility of serum IL-35 in patients with polymyositis and dermatomyositis","volume":"35","author":"Yin","year":"2016","journal-title":"Clinical Rheumatology"},{"key":"10.1016\/j.cyto.2020.155350_b0085","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1056\/NEJM197502132920706","article-title":"Polymyositis and Dermatomyositis: (First of Two Parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"New England J. Med."},{"key":"10.1016\/j.cyto.2020.155350_b0090","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJM197502202920807","article-title":"Polymyositis and Dermatomyositis: (Second of Two Parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"New England J. Med."},{"key":"10.1016\/j.cyto.2020.155350_b0095","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/01.md.0000173991.74008.b0","article-title":"Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian Patients","volume":"84","author":"Troyanov","year":"2005","journal-title":"Medicine"},{"key":"10.1016\/j.cyto.2020.155350_b0100","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/rheumatology\/keg427","article-title":"Development and initial validation of myositis activity and damage indices in patients with adult onset disease","volume":"43","author":"Isenberg","year":"2004","journal-title":"Rheumatology (Oxford, England)"},{"key":"10.1016\/j.cyto.2020.155350_b0105","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/acr.20035","article-title":"Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies","volume":"62","author":"Rider","year":"2010","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.cyto.2020.155350_b0110","doi-asserted-by":"crossref","unstructured":"Bruce B, Fries JF. The Stanford Health Assessment Questionnaire: dimensions and practical applications. Health Qual Life Outcomes 2003 Jun 9; 1:20.","DOI":"10.1186\/1477-7525-1-20"},{"key":"10.1016\/j.cyto.2020.155350_b0115","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.nmd.2007.05.010","article-title":"Muscle lymphocytic infiltrates in thymoma-associated myasthenia gravis are phenotypically different from those in polymyositis","volume":"17","author":"Zamecnik","year":"2007","journal-title":"Neuromuscular Disorders"}],"container-title":["Cytokine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466620303665?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466620303665?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T20:59:18Z","timestamp":1760907558000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043466620303665"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":23,"alternative-id":["S1043466620303665"],"URL":"https:\/\/doi.org\/10.1016\/j.cyto.2020.155350","relation":{},"ISSN":["1043-4666"],"issn-type":[{"type":"print","value":"1043-4666"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interleukin-35 in idiopathic inflammatory myopathies","name":"articletitle","label":"Article Title"},{"value":"Cytokine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cyto.2020.155350","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"155350"}}